We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Finalizes Guidance on Evaluation of Bulk Drug Substance Candidates
FDA Finalizes Guidance on Evaluation of Bulk Drug Substance Candidates
The FDA has issued final guidance clarifying its thought process for evaluating bulk drug substances that are being considered for the 503B bulks list, which specifies substances that outsourcing facilities may use in drug compounding.